Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

2 de julio de 2018 actualizado por: GlaxoSmithKline

Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children

The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.

Descripción general del estudio

Estado

Terminado

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Actual)

3317

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35244
        • GSK Investigational Site
      • Birmingham, Alabama, Estados Unidos, 35205
        • GSK Investigational Site
      • Dothan, Alabama, Estados Unidos, 36305
        • GSK Investigational Site
    • Arkansas
      • Benton, Arkansas, Estados Unidos, 72019
        • GSK Investigational Site
      • Conway, Arkansas, Estados Unidos, 72034
        • GSK Investigational Site
      • Fayetteville, Arkansas, Estados Unidos, 72703
        • GSK Investigational Site
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • GSK Investigational Site
      • Little Rock, Arkansas, Estados Unidos, 72205
        • GSK Investigational Site
    • California
      • Huntington Beach, California, Estados Unidos, 92647
        • GSK Investigational Site
      • Long Beach, California, Estados Unidos, 90806
        • GSK Investigational Site
      • Paramount, California, Estados Unidos, 90723
        • GSK Investigational Site
      • Sacramento, California, Estados Unidos, 95816
        • GSK Investigational Site
      • San Francisco, California, Estados Unidos, 94102
        • GSK Investigational Site
      • West Covina, California, Estados Unidos, 91790
        • GSK Investigational Site
    • Colorado
      • Longmont, Colorado, Estados Unidos, 80501
        • GSK Investigational Site
    • Connecticut
      • Norwich, Connecticut, Estados Unidos, 06360
        • GSK Investigational Site
    • Idaho
      • Nampa, Idaho, Estados Unidos, 83686
        • GSK Investigational Site
    • Illinois
      • DeKalb, Illinois, Estados Unidos, 60115
        • GSK Investigational Site
    • Indiana
      • New Albany, Indiana, Estados Unidos, 47150
        • GSK Investigational Site
    • Kansas
      • Arkansas City, Kansas, Estados Unidos, 67005
        • GSK Investigational Site
      • Newton, Kansas, Estados Unidos, 67114
        • GSK Investigational Site
      • Wichita, Kansas, Estados Unidos, 67207
        • GSK Investigational Site
    • Kentucky
      • Bardstown, Kentucky, Estados Unidos, 40004
        • GSK Investigational Site
      • Louisville, Kentucky, Estados Unidos, 40207
        • GSK Investigational Site
    • Louisiana
      • Bossier City, Louisiana, Estados Unidos, 71111
        • GSK Investigational Site
      • Metairie, Louisiana, Estados Unidos, 70006
        • GSK Investigational Site
    • Michigan
      • Stevensville, Michigan, Estados Unidos, 49127
        • GSK Investigational Site
    • Minnesota
      • Saint Paul, Minnesota, Estados Unidos, 55108
        • GSK Investigational Site
    • Missouri
      • Saint Louis, Missouri, Estados Unidos, 63141
        • GSK Investigational Site
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68134
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, Estados Unidos, 89015
        • GSK Investigational Site
    • New York
      • Cortland, New York, Estados Unidos, 13045
        • GSK Investigational Site
    • North Carolina
      • Boone, North Carolina, Estados Unidos, 28607
        • GSK Investigational Site
      • Cary, North Carolina, Estados Unidos, 27518
        • GSK Investigational Site
      • Raleigh, North Carolina, Estados Unidos, 27609
        • GSK Investigational Site
    • North Dakota
      • Fargo, North Dakota, Estados Unidos, 58103
        • GSK Investigational Site
    • Ohio
      • Austintown, Ohio, Estados Unidos, 44515
        • GSK Investigational Site
      • Cincinnati, Ohio, Estados Unidos, 45245
        • GSK Investigational Site
      • Cleveland, Ohio, Estados Unidos, 44121
        • GSK Investigational Site
      • Dayton, Ohio, Estados Unidos, 45406
        • GSK Investigational Site
    • Oregon
      • Gresham, Oregon, Estados Unidos, 97030
        • GSK Investigational Site
    • Pennsylvania
      • Erie, Pennsylvania, Estados Unidos, 16505
        • GSK Investigational Site
      • Greenville, Pennsylvania, Estados Unidos, 16125
        • GSK Investigational Site
      • Latrobe, Pennsylvania, Estados Unidos, 15650
        • GSK Investigational Site
      • Pittsburgh, Pennsylvania, Estados Unidos, 15236
        • GSK Investigational Site
      • Uniontown, Pennsylvania, Estados Unidos, 15401
        • GSK Investigational Site
      • Wexford, Pennsylvania, Estados Unidos, 15090
        • GSK Investigational Site
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29406
        • GSK Investigational Site
    • Tennessee
      • Clarksville, Tennessee, Estados Unidos, 37043
        • GSK Investigational Site
      • Jackson, Tennessee, Estados Unidos, 38305
        • GSK Investigational Site
      • Kingsport, Tennessee, Estados Unidos, 37660
        • GSK Investigational Site
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • GSK Investigational Site
      • Fort Worth, Texas, Estados Unidos, 76135
        • GSK Investigational Site
      • Houston, Texas, Estados Unidos, 77055
        • GSK Investigational Site
      • San Angelo, Texas, Estados Unidos, 76904
        • GSK Investigational Site
    • Utah
      • Bountiful, Utah, Estados Unidos, 84010
        • GSK Investigational Site
      • Layton, Utah, Estados Unidos, 84041
        • GSK Investigational Site
      • Murray, Utah, Estados Unidos, 84107
        • GSK Investigational Site
      • Provo, Utah, Estados Unidos, 84604
        • GSK Investigational Site
      • Roy, Utah, Estados Unidos, 84067
        • GSK Investigational Site
      • South Jordan, Utah, Estados Unidos, 84095
        • GSK Investigational Site
    • Virginia
      • Burke, Virginia, Estados Unidos, 22015
        • GSK Investigational Site
      • Pokfulam, Hong Kong
        • GSK Investigational Site
      • Shatin, Hong Kong
        • GSK Investigational Site
      • Mexico, México, 6720
        • GSK Investigational Site
      • Mexico city, México, 04530
        • GSK Investigational Site
      • Bangkok, Tailandia, 10400
        • GSK Investigational Site
      • Taipei, Taiwán, 104
        • GSK Investigational Site
      • Taipei, Taiwán
        • GSK Investigational Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 meses a 2 años (Niño)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
  • Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the subject's parent/guardian.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
  • History of hypersensitivity to any vaccine.
  • History of allergy or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment.
  • History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
  • Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
  • Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Fluarix Dose A Group

Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
Experimental: Fluarix Dose B Group

Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
Comparador activo: Fluzone Group

Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).

* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses.

One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Periodo de tiempo: Day 0 (PRE), Day 28 or Day 56 (POST)

GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine.

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 0 (PRE), Day 28 or Day 56 (POST)
Number of Subjects Who Seroconverted
Periodo de tiempo: Day 28 or Day 56

Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer.

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 28 or Day 56

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Seroprotected Subjects
Periodo de tiempo: Day 0 (PRE), Day 28 or Day 56 (POST)

A seroprotected subject is a subject with a serum anti-HA titer

≥ 1:40

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 0 (PRE), Day 28 or Day 56 (POST)
Seroconversion Factor
Periodo de tiempo: Day 28 or Day 56

Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0).

Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects

Day 28 or Day 56
Number of Subjects Reporting Solicited Local Symptoms
Periodo de tiempo: During a 4-day follow-up period after vaccination
Solicited local symptoms assessed include pain, redness and swelling.
During a 4-day follow-up period after vaccination
Number of Subjects Reporting Solicited General Symptoms
Periodo de tiempo: During a 4-day follow-up period after vaccination
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
During a 4-day follow-up period after vaccination
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Periodo de tiempo: During a 28-day follow-up period after vaccination
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
During a 28-day follow-up period after vaccination
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Periodo de tiempo: During the entire study (Day 0 until Month 6)

An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.

NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders

During the entire study (Day 0 until Month 6)
Number of Subjects Reporting Rare Serious Events
Periodo de tiempo: During the entire study (Day 0 until Month 6)
Rare serious events have an occurrence rate of 1/300 (0.3%).
During the entire study (Day 0 until Month 6)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de octubre de 2008

Finalización primaria (Actual)

5 de marzo de 2009

Finalización del estudio (Actual)

1 de junio de 2009

Fechas de registro del estudio

Enviado por primera vez

1 de octubre de 2008

Primero enviado que cumplió con los criterios de control de calidad

1 de octubre de 2008

Publicado por primera vez (Estimar)

2 de octubre de 2008

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

31 de julio de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

2 de julio de 2018

Última verificación

1 de octubre de 2016

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Datos del estudio/Documentos

  1. Especificación del conjunto de datos
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  2. Formulario de consentimiento informado
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  3. Plan de Análisis Estadístico
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  4. Formulario de informe de caso anotado
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  5. Informe de estudio clínico
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  6. Conjunto de datos de participantes individuales
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
  7. Protocolo de estudio
    Identificador de información: 111751
    Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir